These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 18824611

  • 1. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
    Camargo IL, Neoh HM, Cui L, Hiramatsu K.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4289-99. PubMed ID: 18824611
    [Abstract] [Full Text] [Related]

  • 2. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS, Jones RN, Rossi KL, Rybak MJ.
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [Abstract] [Full Text] [Related]

  • 3. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 4. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
    Bowker KE, Noel AR, MacGowan AP.
    J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 6. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [Abstract] [Full Text] [Related]

  • 7. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
    Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC.
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 9. [In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates to vancomycin, teicoplanin, linezolide and daptomycin].
    Celikbilek N, Ozdem B, Gürelik FC, Güvenman S, Güner HR, Açıkgöz ZC.
    Mikrobiyol Bul; 2011 Jul; 45(3):512-8. PubMed ID: 21935784
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
    Sader HS, Becker HK, Moet GJ, Jones RN.
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
    [Abstract] [Full Text] [Related]

  • 11. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
    Torrico M, Giménez MJ, González N, Alou L, Sevillano D, Cafini F, Prieto J, Cleeland R, Aguilar L.
    Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
    [Abstract] [Full Text] [Related]

  • 12. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, Stefani S.
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [Abstract] [Full Text] [Related]

  • 13. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
    Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC, Eliopoulos GM.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2223-5. PubMed ID: 17404001
    [Abstract] [Full Text] [Related]

  • 14. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR.
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [Abstract] [Full Text] [Related]

  • 15. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
    Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, Watanabe Y, Shoji M, Hishinuma T, Hiramatsu K.
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5222-33. PubMed ID: 20837752
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.
    Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS.
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2312-8. PubMed ID: 19332678
    [Abstract] [Full Text] [Related]

  • 18. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, meticillin-resistant Staphylococcus aureus in a patient with chronic kidney disease.
    Kuo CC, Wu VC, Huang YT, Liao CH, Hsueh PR.
    Int J Antimicrob Agents; 2009 Jan; 33(1):96-8. PubMed ID: 18790610
    [No Abstract] [Full Text] [Related]

  • 19. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW, Murray CK, Holmes RL, Patterson JE, Jorgensen JH.
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.
    Patel D, Husain M, Vidaillac C, Steed ME, Rybak MJ, Seo SM, Kaatz GW.
    Int J Antimicrob Agents; 2011 Nov; 38(5):442-6. PubMed ID: 21840181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.